Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
  • A61P5/30—Oestrogens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to therapeutic agents that are tissue selective estrogen agonist/antagonist compounds that have been found to be useful in the treatment and prevention of cardiovascular disease in postmenopausal women.
• This invention provides a method for the prevention and treatment of cardiovascular disease in postmenopausal women without having an overt uterotrophic effect, or promoting an increased risk of breast cancer or causing an increased incidence of vaginal bleeding and breast tenderness
• the method comprises administering to a human in need thereof an effective amount of a compound of formula I
• X represents 3- or 4- lodo or bromo and the R-* and Rr symbols, which may be the same or different, represent Cj-3 alkyl, especially methyl or ethyl, groups or R 1 - represents a hydrogen atom and R2 a C1.3 alkyl group or R-- and R2 together with the nitrogen atom to which they are attached represent a saturated heterocyclic group, typically having 5 or 6 ring atoms, especially a pyrrolidmo, pipendino, 4- methylpipe ⁇ dino or morpholino group, and their pharmaceutically acceptable acid addition salts
• the present invention is a therapeutic method for preventing and treating cardiovascular disease in postmenopausal women with a group of compounds that have been previously prepared and evaluated as effective in the treatment of estrogen receptor-positive breast cancer These compounds are described in formula I above and in U S. patent 4,839,155
• the preferred compound for the described method of treatment is
• Such compounds are known to bind to the estrogen receptor and to cause either estrogen agonist or antagonist effects depending on the tissue bemg studied
• a beneficial effect on cardiovascular disease would be produced by estrogen agonist effects on the liver ( to alter the hpid profile and levels of fibinogen)
• estrogen agonist effects on the arterial wall may also contribute to a reduction in the risk of cardiovascular disease.
• cardiovascular disease refers to atherosclerotic cardiovascular diseases such as myocardial infarction, stroke, angina, intermittent claudication transient blindness, transient lschemic attacks (TIA) and peripheral vascular disease.
• the method of this invention is useful in producing a plasma lipid profile that is associated with a reduced risk of atherosclerosis and a reduction of raised LDL cholesterol levels Additionally this method is useful in producing a reduction of other independent cardiovascular risk factors such as plasma fibnnogen levels and serum levels of lp(a).
• the ability to reduce the risk of cardiovascular disease is assessed by studies of the effect of idoxifene a number of different risk factors for cardiovascular disease in postmenopausal women. These include different parameters of the pid profile and levels of coagulation and fib ⁇ nolysis markers.
• the compounds of the instant invention and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
• a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carner(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or colonng agent
• a suitable liquid carner(s) for example, ethanol, glycerine, non-aqueous solvent, for example, polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or colonng agent
• a composition in the form of a tablet can be prepared using any suitable pharmaceutical car ⁇ er(s) routinely used for prepa ⁇ ng solid formulations Examples of such earners include magnesium stearate, starch, lactose, sucrose and cellulose
• a composition in the form of a capsule can be prepared using routine encapsulation procedures.
• pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule: alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carner(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
• a suitable pharmaceutical carner(s) for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
• the compounds of the instant invention and their pharmaceutically acceptable salts which are active when administered parenterally can be formulated as solutions or suspensions.
• a composition for parenteral administration will generally consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrro done, lecithin, arachis oil or sesame oil.
• a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrro done, lecithin, arachis oil or sesame oil.
• the solution can be lyophi sed and then reconstituted with a suitable solvent just prior to administration
• a typical suppository composition comprises a compound of the instant invention or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or coca butter or other low melting vegetable or synthetic waxes or fats
• a typical transdermal formulation comprises a conventional aqueous or non- aqueous vehicle, for example, a cream, ointment lotion or paste or in the form of a medicated plaster, patch or membrane
• the pharmaceutical compositions adapted include solutions, suspensions, ointments, and solid inserts
• Typical pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or vegetable oils, and water soluble ophthalmologically acceptable non-toxic polymers, for example, cellulose derivatives such as methyl cellulose
• the pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting and bodying agents, as for example, polyethylene glycols, antibacterial components such as quaternary ammonium compounds; buffering ingredients such as alkali metal chloride, antioxidants such as sodium metabisulfite, and other conventional ingredients such as sorbitan monolaurate
• the composition is in unit dose form.
• Doses of the compounds of the instant invention in a pharmaceutical dosage unit will be an efficacious, non- toxic quantity selected from the range of 01 - 200 mg/kg of active compound, preferably 1 - 100 mg/kg.
• the selected dose is administered to a human patient in need of treatment or prevention of cardiovascular disease is or in the lowering of plasma cholesterol from 1-6 times daily, orally, rectally, topically, by injection, or continuously by infusion
• Oral dosage units for human administration preferably contain from 10 to 500 mg of active compound Lower dosages are used generally for parenteral administration
• Oral administration is used when safe, effective, and convenient for the patient
• An oral dosage form for administering orally active Formula (I) compounds is produced by screening, mixing and filling into hard gelatin capsules the ingredients in proportions, for example, as shown below
• sucrose calcium sulfate dihydrate and orally active Formula (I) compounds are mixed and granulated with a 10% gelatmg solution.
• the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pyrrole Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Saccharide Compounds (AREA)
• Pyridine Compounds (AREA)

Applications Claiming Priority (5)

Publications (2)

Family

ID=26699738

Family Applications (2)

Family Applications After (1)

Country Status (16)

Families Citing this family (5)

Citations (2)

Family Cites Families (6)

• 1997
  • 1997-08-29 AR ARP970103968A patent/AR008155A1/es unknown
  • 1997-09-03 KR KR1019997001861A patent/KR20000068473A/ko not_active Application Discontinuation
  • 1997-09-03 BR BR9711676A patent/BR9711676A/pt not_active Application Discontinuation
  • 1997-09-03 TR TR1999/00506T patent/TR199900506T2/xx unknown
  • 1997-09-03 WO PCT/US1997/015475 patent/WO1998009619A1/en not_active Application Discontinuation
  • 1997-09-03 PL PL97332278A patent/PL332278A1/xx unknown
  • 1997-09-03 AU AU44097/97A patent/AU4409797A/en not_active Abandoned
  • 1997-09-03 JP JP51283798A patent/JP2002515046A/ja active Pending
  • 1997-09-03 EP EP97942388A patent/EP0927029A4/en not_active Withdrawn
  • 1997-09-03 WO PCT/US1997/015474 patent/WO1998009519A1/en not_active Application Discontinuation
  • 1997-09-03 TR TR1999/00504T patent/TR199900504T2/xx unknown
  • 1997-09-03 PL PL97332038A patent/PL332038A1/xx unknown
  • 1997-09-03 CN CN97199493A patent/CN1236313A/zh active Pending
  • 1997-09-03 JP JP51283898A patent/JP2002515047A/ja active Pending
  • 1997-09-03 CA CA002264943A patent/CA2264943A1/en not_active Abandoned
  • 1997-09-03 CA CA002264775A patent/CA2264775A1/en not_active Abandoned
  • 1997-09-03 BR BR9711681A patent/BR9711681A/pt not_active Application Discontinuation
  • 1997-09-03 CZ CZ99766A patent/CZ76699A3/cs unknown
  • 1997-09-03 CN CN97199492A patent/CN1236299A/zh active Pending
  • 1997-09-03 IL IL12864597A patent/IL128645A0/xx unknown
  • 1997-09-03 KR KR1019997001860A patent/KR20000068472A/ko not_active Application Discontinuation
  • 1997-09-03 AU AU42473/97A patent/AU4247397A/en not_active Abandoned
  • 1997-09-03 EP EP97940773A patent/EP0929216A4/en not_active Withdrawn
  • 1997-09-04 CO CO97051289A patent/CO5070658A1/es unknown
  • 1997-09-04 CO CO97051287A patent/CO4920218A1/es unknown
  • 1997-12-11 TW TW086112930A patent/TW411273B/zh active
• 1999
  • 1999-03-05 NO NO991097A patent/NO991097D0/no not_active Application Discontinuation
  • 1999-03-05 NO NO991096A patent/NO991096L/no not_active Application Discontinuation

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events